Cronos Group (CRON) Projected to Post Quarterly Earnings on Thursday

Cronos Group (NASDAQ:CRON) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cronos Group to post earnings of $0.01 per share and revenue of $38.5060 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Cronos Group Price Performance

Shares of NASDAQ CRON opened at $2.67 on Thursday. Cronos Group has a one year low of $1.60 and a one year high of $3.43. The firm’s 50 day simple moving average is $2.70 and its two-hundred day simple moving average is $2.58. The stock has a market capitalization of $1.02 billion, a P/E ratio of 26.70 and a beta of 0.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC grew its position in shares of Cronos Group by 12.5% in the 4th quarter. Headlands Technologies LLC now owns 63,097 shares of the company’s stock worth $166,000 after buying an additional 6,998 shares during the last quarter. Federation des caisses Desjardins du Quebec lifted its stake in Cronos Group by 169.7% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 16,371 shares of the company’s stock worth $42,000 after acquiring an additional 10,300 shares during the period. Brooklyn Investment Group boosted its holdings in Cronos Group by 5,733.0% in the third quarter. Brooklyn Investment Group now owns 10,966 shares of the company’s stock valued at $30,000 after acquiring an additional 10,778 shares in the last quarter. Scientech Research LLC bought a new stake in Cronos Group in the third quarter valued at $32,000. Finally, Swiss National Bank increased its position in Cronos Group by 3.1% during the 4th quarter. Swiss National Bank now owns 417,200 shares of the company’s stock valued at $1,096,000 after purchasing an additional 12,400 shares during the period. Institutional investors own 8.71% of the company’s stock.

Analyst Ratings Changes

CRON has been the topic of several recent research reports. Canaccord Genuity Group began coverage on shares of Cronos Group in a report on Tuesday, January 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cronos Group in a research note on Monday, December 29th. Wall Street Zen upgraded Cronos Group from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Zacks Research cut Cronos Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $2.30 price target on shares of Cronos Group in a research report on Wednesday, January 14th. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Cronos Group currently has an average rating of “Hold” and a consensus target price of $2.30.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.